Literature DB >> 16524776

Persistence of antibodies after vaccination against tick-borne encephalitis.

Pamela Rendi-Wagner1, Olaf Zent, Wolfgang Jilg, Annelie Plentz, Jiri Beran, Herwig Kollaritsch.   

Abstract

Active vaccination against the tick-borne encephalitis (TBE) virus has successfully been implemented in endemic countries for many years. However, little was known about persistency of antibodies after completion of the primary vaccination and/or TBE booster immunization. Five recently performed serological follow-up studies in adults have now revealed that the persistence of protective immunity following at least one booster immunization was longer than expected. Notably, studies which analyzed different age groups indicate differences between younger adults aged 18-49 years and older adults aged > or = 50 years with respect to TBE antibody persistence and the immune response following a subsequent booster dose. To summarize, the serological studies included in this analysis generally support a reconsideration of current TBE booster recommendations and a prolongation of booster intervals at least in younger adults.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524776     DOI: 10.1016/j.ijmm.2006.01.030

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  7 in total

1.  Mechanistic insights into the impairment of memory B cells and antibody production in the elderly.

Authors:  Judith H Aberle; Karin Stiasny; Michael Kundi; Franz X Heinz
Journal:  Age (Dordr)       Date:  2012-01-27

2.  TBE--update on vaccination recommendations for children, adolescents, and adults.

Authors:  Tomas Jelinek
Journal:  Wien Med Wochenschr       Date:  2012-06-12

3.  High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.

Authors:  Jörg Schüpbach; Leslie R Bisset; Stephan Regenass; Philippe Bürgisser; Meri Gorgievski; Ingrid Steffen; Corinne Andreutti; Gladys Martinetti; Cyril Shah; Sabine Yerly; Thomas Klimkait; Martin Gebhardt; Franziska Schöni-Affolter; Martin Rickenbach; J Barth; M Battegay; E Bernascon; J Böni; H C Bucher; P Bürgisser; C Burton-Jeangros; A Calmy; M Cavassini; R Dubs; M Egger; L Elzi; J Fehr; M Fischer; M Flepp; P Francioli; H Furrer; C A Fux; M Gorgievski; H Günthard; B Hasse; H H Hirsch; B Hirschel; I Hösli; C Kahlert; L Kaiser; O Keiser; C Kind; T Klimkait; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; N Müller; D Nadal; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; P Schmid; D Schultze; F Schöni-Affolter; J Schüpbach; R Speck; P Taffé; A Telenti; A Trkola; P Vernazza; V von Wyl; R Weber; S Yerly
Journal:  BMC Infect Dis       Date:  2011-09-26       Impact factor: 3.090

4.  Patients with breakthrough tick-borne encephalitis suffer a more severe clinical course and display extensive magnetic resonance imaging changes.

Authors:  J N Wagner; M Sonnberger; A Troescher; I Krehan; A Hauser; J Panholzer; T J von Oertzen
Journal:  Eur J Neurol       Date:  2020-05-19       Impact factor: 6.089

5.  Immunological Memory and Affinity Maturation After Vaccination in Patients With Propionic Acidemia.

Authors:  Manuela Zlamy; Thomas Zöggeler; Magdalena Bachmann; Michael Schirmer; Christian Lechner; Miriam Michel; Alexander Schimkowitsch; Daniela Karall; Sabine Scholl-Bürgi
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

6.  Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals.

Authors:  Pontus Lindblom; Peter Wilhelmsson; Linda Fryland; Andreas Matussek; Mats Haglund; Johanna Sjöwall; Sirkka Vene; Dag Nyman; Pia Forsberg; Per-Eric Lindgren
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

Review 7.  Primary vaccine failure to routine vaccines: Why and what to do?

Authors:  Ursula Wiedermann; Erika Garner-Spitzer; Angelika Wagner
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.